The institute seminar on Wednesday February 13th will be held by Jostein Dahle, head of the Radiotherapy project group at the Department of Radiation Biology.
The title of his talk is "Alpha‐particle based radioimmunotherapy of cancer"
Time and place: 12:00, Seminar Room, F4, Institute for Cancer Research.
From major journals, first or last author from the Institute for Cancer Research
Ianevski A, Giri AK, Aittokallio T(2022) SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples Nucleic Acids Res(in press) DOI 10.1093/nar/gkac382, PubMed 35580060
Kidd SG, Bogaard M, Carm KT, Bakken AC, Maltau AMV, Løvf M, Lothe RA, Axcrona K, Axcrona U, Skotheim RI(2022) In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis Mol Oncol(in press) DOI 10.1002/1878-0261.13225, PubMed 35574900
Khadse A, Haakensen VD, Silwal-Pandit L, Hamfjord J, Micke P, Botling J, Brustugun OT, Lingjærde OC, Helland Å, Kure EH(2022) Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma Front Oncol, 12, 873532 DOI 10.3389/fonc.2022.873532, PubMed 35574381
Ianevski A, Giri AK, Aittokallio T(2022) SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples Nucleic Acids Res(in press) DOI 10.1093/nar/gkac382, PubMed 35580060
Kidd SG, Bogaard M, Carm KT, Bakken AC, Maltau AMV, Løvf M, Lothe RA, Axcrona K, Axcrona U, Skotheim RI(2022) In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis Mol Oncol(in press) DOI 10.1002/1878-0261.13225, PubMed 35574900
Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich Det al.(2022) Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway J Transl Med, 20(1), 225 DOI 10.1186/s12967-022-03432-5, PubMed 35568909